Babyl & Novo Nordisk partner to provide an innovative approach to diabetes awareness and care in Rwanda
December 01 2022 - 3:00AM
Business Wire
Babyl, a subsidiary of Babylon (NYSE: BBLN), and Novo Nordisk
announced today that they have entered an innovative partnership to
contribute to the expansion of diabetes awareness and care in
Rwanda. Drawing on Novo Nordisk’s expertise and mission to drive
change to defeat diabetes and Babyl’s existing infrastructure and
experience in delivering digital health services at scale in
Rwanda, this new joint initiative aims to improve awareness, care
and management of diabetes through community engagement, skills
building and use of Babyl’s advanced digital technology.
By offering digital consultations to patients across Rwanda,
Babyl’s service will support people in better understanding the
symptoms that they are experiencing as well as supporting patients
with a confirmed diabetes diagnosis to manage their chronic
condition from the ease and privacy of their own mobile phone.
Patients will be consulted by a doctor or a nurse and guided to the
appropriate level of care they need including medication and
referral for laboratory tests.
“Our data shows that a lot of people living with diabetes are
unaware of it, and that many people already diagnosed are unable to
access the care they need,” said Vinay Ransiwal, Vice President and
General Manager Novo Nordisk Middle Africa. “Allowing a much wider
access to care through Babyl’s long-proven digital platform, backed
by specialists, offers an exciting opportunity to significantly
scale up access to diabetes care and, hence, reach many more people
with diabetes with the care they need. We are confident that
together we can drive change to defeat diabetes in Middle
Africa.”
To support the initiative, Babyl will be rolling out a training
scheme for clinicians to digitally provide diabetes care for
patients, drawing on Novo Nordisk’s global expertise and best
practices. This increased capacity of health providers to screen
and manage diabetes cases will help Babyl to provide patients with
effective and consistent care.
Babyl will also deliver a health education campaign that builds
greater awareness around diabetes and its health risks to encourage
prevention, early detection and adherence to disease management
among the broader Rwandan population.
“Screening, managing and follow-up of diabetes in patients is a
significant challenge for Rwanda’s health sector and digitization
could be a game changer,” said Dr. Simba Calliope, Medical
Director, Babyl. “We are so excited about this cutting edge
partnership with Novo Nordisk that allows Babyl to strengthen our
offering to patients and raise awareness of diabetes. This is an
important issue in the country and a government priority.”
About Babylon
At Babylon, our mission is to make quality healthcare accessible
and affordable for every person on Earth. To this end we are
building an integrated digital first primary care service that can
manage population health at scale.
Founded in 2013, we are reengineering how people engage with
their care at every step of the healthcare continuum. By flipping
the model from reactive sick care to proactive healthcare through
the devices people already own, we offer millions of people
globally, ongoing, always-on care. And, we have already shown that
in environments as diverse as the developed UK or developing
Rwanda, urban New York or rural Missouri, for people of all ages,
it is possible to achieve our mission by leveraging our highly
scalable, digital-first platform combined with high quality,
virtual clinical operations to provide integrated, personalized
healthcare.
Today, we support a global patient network across 15 countries,
and operate in 16 languages. In 2021 alone, Babylon helped a
patient every 6 seconds, with approximately 5.2 million
consultations and AI interactions. Importantly, this was achieved
with a 93% user retention rate in our NHS GP at Hand service and 4
or 5-star ratings from more than 90% of our users across all of our
geographies. We are working to demonstrate how our model of digital
first integrated primary care can be applied to manage the health
of the population in different settings across Medicare, Medicaid,
and commercial value based care contracts in the US and our primary
care services in the UK.
Babylon is also working with governments, health providers,
employers and insurers across the globe to provide them with a new
digital-first platform that any partner can use to deliver
high-quality healthcare with lower costs and better outcomes. For
more information, please visit www.babylonhealth.com.
About Babyl
Babyl Rwanda is a subsidiary of Babylon and is the largest
digital medical consultation service provider in Rwanda since 2016.
Babyl has signed a 10-year partnership with the Government of
Rwanda in early 2020 to develop a new healthcare delivery model of
‘Digital-First Integrated Care’, where all Rwandans are able to
gain access to qualified doctors and nurses through their mobile
phone.
RSSB & Mutuelle insurance, Britam members have access to the
service. To date, Babyl has over 2.5 million registered users &
carries out up to 3,500 consultations a day.
For more information about Babyl, visit
https://www.babyl.rw/
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo
Nordisk employs about 45,800 people in 80 countries and markets its
products in around 170 countries. For more information, visit
novonordisk.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221201005014/en/
Elizabeth Tew press@babylonhealth.com
Nadege Nahimana nadege.nahimana@babyl.rw
Babylon (NYSE:BBLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Babylon (NYSE:BBLN)
Historical Stock Chart
From Apr 2023 to Apr 2024